Clinical Studies Sponsored by argenx

A Study of Efgartigimod PH20 SC in Adults With Thyroid Eye Disease

A Study of Efgartigimod PH20 SC in Adults With Thyroid Eye Disease

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults with Systemic Sclerosis

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding

A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)

A Study to Assess Adults with CIDP Transitioning from IVIg to Efgartigimod PH20 SC

A Study of Empasiprubart's Effect on the Body, Levels in the Blood, Effectiveness, and Safety in Adults With Dermatomyositis

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)